Docetaxel loaded PEG-PLGA nanoparticles: Optimized drug loading, in-vitro cytotoxicity and in-vivo antitumor effect

Iranian Journal of Pharmaceutical Research

Volumn 13, Issue 3, 2014, Pages 819-834

  Koopaei, Mona Noori ^a   Khoshayand, Mohammad Reza ^a   Mostafavi, Seyed Hossein ^a   Amini, Mohsen ^a   Khorramizadeh, Mohammad Reza ^b   Tehrani, Mahmood Jeddi ^c   Atyabi, Fatemeh ^a   Dinarvand, Rassoul ^a  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c AVICENNA RESEARCH INSTITUTE   (Iran)

Author keywords

Anti tumor; Box behnken; Docetaxel; Experimental design; Nanoparticles; Pegylation; PLGA

Indexed keywords

DOCETAXEL; NANOPARTICLE; POLYGLACTIN; SOLVENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG RELEASE; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; MOUSE; MTT ASSAY; NEOPLASM; NONHUMAN; PARTICLE SIZE; PROCESS OPTIMIZATION; PROTON NUCLEAR MAGNETIC RESONANCE; SCANNING ELECTRON MICROSCOPY; TUMOR VOLUME;

EID: 84905120119     PISSN: 17350328     EISSN: 17266890     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Brigger I, Dubernet C and Couvreur P. Nanoparticles in cancer therapy and diagnosis. Adv. Drug Deliv. Rev. (2012) 54: 631-651.
2. Sahoo SK and Labhasetwar V. Nanotech approaches to drug delivery and imaging. Drug Discov. Today (2003) 8: 1112-1120.
3. Dinarvand R, Sepehri N, Manoochehri S, Rouhani H and Atyabi F. Polylactide-co-glycolide nanoparticles for controlled delivery of anticancer agents. Int. J. Nanomed. (2011) 6: 877-895.
4. Park J, Fong PM, Lu J, Russell KS, Booth CJ, Saltzman WM and Fahmy TM. PEGylated PLGA nanoparticles for the improved delivery of doxorubicin. Nanomed. Nanotechnol. Biol. Med. (2009) 5: 410-418.
5. Betancourt T, Brown B and Brannon-Peppas L. Doxorubicin-loaded PLGA nanoparticles by nanoprecipitation: preparation, characterization and in-vitro evaluation. Nanomed. Nanotechnol. Biol. Med. (2007) 2: 219-232.
6. Goren D, Horowitz AT, Tzemach D, Tarshish M, Zalipsky S and Gabizon A. Nuclear delivery of doxorubicin via folate-targeted liposomes with bypass of multidrug-resistance efflux pump. Clin. Cancer Res. (2000) 6: 1949-1957.
7. Chan JM, Zhang L, Yuet KP, Liao G, Rhee J-W, Langer R and Farokhzad OC. PLGA-lecithin-PEG core-shell nanoparticles for controlled drug delivery. Biomat. (2009) 30: 1627-1634.
8. Cheng J, Teply BA, Sherifi I, Sung J, Luther G, Gu FX, Levy-Nissenbaum E, Radovic-Moreno AF, Langer R and Farokhzad OC. Formulation of functionalized PLGA-PEG nanoparticles for in-vivo targeted drug delivery. Biomat. (2007) 28: 869-876.
9. Danhier F, Ucakar B, Magotteaux N, Brewster ME and Préat V. Active and passive tumor targeting of a novel poorly soluble cyclin dependent kinase inhibitor, JNJ-7706621. Int. J. Pharm. (2010) 392: 20-28.
10. Xu Z, Chen L, Gu W, Gao Y, Lin L, Zhang Z, Xi Y and Li Y. The performance of docetaxel-loaded solid lipid nanoparticles targeted to hepatocellular carcinoma. Biomat. (2009) 30: 226-232.
11. Musumeci T, Ventura CA, Giannone I, Ruozi B, Montenegro L, Pignatello R and Puglisi G. PLA/PLGA nanoparticles for sustained release of docetaxel. Int. J. Pharm. (2006) 325: 172-179.
12. Moraes CM, de Lima R, Rosa AH, de Paula E and Fraceto LF (eds.) Encapsulation of Local Anesthetic Bupivacaine in Biodegradable Poly (DL-lactide-co-glycolide) Nanospheres: Factorial Design, Characterization and Cytotoxicity Studies. Macromolecular Symposia;: Wiley Online Library (2009) 106-112.
13. Ferreira SLC, Bruns R, Ferreira H, Matos G, David J, Brandao G, da Silva EG, Portugal LA, dos Reis PS, Souza AS and dos Santos WN. Box-Behnken design: An alternative for the optimization of analytical methods. Anal. chim. acta. (2007) 597: 179-186.
14. Loveymi BD, Jelvehgari M, Zakeri-Milani P and Valizadeh H. Statistical optimization of oral vancomycin-eudragit rs nanoparticles using response surface methodology. Iran. J. Pharm. Res. (2012) 11: 1001-1012.
15. Patel A, Ray S and Thakur RS. In-vitro evaluation and optimization of controlled release floating drug delivery system of metformin hydrochloride. DARU J. Pharm. Sci. (2006) 14: 57-64.
16. Woitiski CB, Veiga F, Ribeiro A and Neufeld R. Design for optimization of nanoparticles integrating biomaterials for orally dosed insulin. Europ. J. Pharm. Biopharm. (2009) 73: 25-33.
17. Esmaeili F, Atyabi F and Dinarvand R. Preparation of PLGA nanoparticles using TPGS in the spontaneous emulsification solvent diffusion method. J. Experi. Nanosci. (2007) 2: 183-192.
18. Gazori T, Khoshayand MR, Azizi E, Yazdizade P, Nomani A and Haririan I. evaluation of alginate/ chitosan nanoparticles as antisense delivery vector: formulation, optimization and in-vitro characterization. Carbohydrate Polymers (2009) 77: 599-606.
19. Myers RH and Montgomery DC. Process and Product Optimization Using Designed Experiments, Response Surface Methodology (1997) 343-351.
20. Kim MS, Kim JS, You YH, Park HJ, Lee S, Park JS, Woo JS and Hwang SJ. Development and optimization of a novel oral controlled delivery system for tamsulosin hydrochloride using response surface methodology. Int. J. Pharm. (2007) 341: 97-104.
21. Motwani SK, Chopra S, Talegaonkar S, Kohli K, Ahmad FJ and Khar RK. Chitosan-sodium alginate nanoparticles as submicroscopic reservoirs for ocular delivery: Formulation, optimisation and in-vitro characterisation. Europ. J. Pharm. Biopharm. (2008) 68: 513-525.
22. Harrington E. The desirability function. Indust. Quality Control (1965) 21: 494-498.
23. Derringer G. Simultaneous optimization of several response variables. J. Quality Technol. (1980) 12: 214-219.
24. Esmaeili F, Dinarvand R, Ghahremani MH, Ostad SN, Esmaily H and Atyabi F. Cellular cytotoxicity and in-vivo biodistribution of docetaxel poly (lactide-co-glycolide) nanoparticles. Anti-Cancer Drugs (2010) 21: 43.
25. Koopaei MN, Dinarvand R, Amini M, Rabbani H, Emami S, Ostad SN and Atyabi F. Docetaxel immunonanocarriers as targeted delivery systems for HER 2-positive tumor cells: preparation, characterization, and cytotoxicity studies. Int. J. Nanomed. (2011) 6: 1903.
26. Taheri A, Dinarvand R, Nouri FS, Khorramizadeh MR, Borougeni AT, Mansoori P and Atyabi F. Use of biotin targeted methotrexate-human serum albumin conjugated nanoparticles to enhance methotrexate antitumor efficacy. Int. J. Nanomed. (2011) 6: 1863.
27. Budhian A, Siegel SJ and Winey KI. Production of haloperidol-loaded PLGA nanoparticles for extended controlled drug release of haloperidol. J. Microencapsul. (2005) 22: 773-785.
28. Görner T, Gref R, Michenot D, Sommer F, Tran M and Dellacherie E. Lidocaine-loaded biodegradable nanospheres. I. Optimization of the drug incorporation into the polymer matrix. J. Control Release (1999) 57: 259-268.
29. Panyam J and Labhasetwar V. Dynamics of endocytosis and exocytosis of poly (D, L-lactide-co-glycolide) nanoparticles in vascular smooth muscle cells. Pharm. Res. (2003) 20: 212-220.
30. Ebrahimnejad P, Dinarvand R, Sajadi A, Jaafari MR, Nomani AR, Azizi E, Rad-Malekshahi M and Atyabi F. Preparation and in-vitro evaluation of actively targetable nanoparticles for SN-38 delivery against HT-29 cell lines. Nanomed. Nanotechnol. Biol. Med. (2010) 6: 478-485.
31. Esmaeili F, Ghahremani MH, Ostad SN, Atyabi F, Seyedabadi M, Malekshahi MR, Amini M and Dinarvand R. Folate-receptor-targeted delivery of docetaxel nanoparticles prepared by PLGA-PEG-folate conjugate. J. Drug Target. (2008) 16: 415-423.
32. Gabizon AA. Selective tumor localization and improved therapeutic index of anthracyclines encapsulated in long-circulating liposomes. Cancer Res. (1992) 52: 891-896.